TABLE 3.
Median Incidence (25th–75th percentile)* | |||
---|---|---|---|
|
|||
Age, y | Men | Women | Total |
| |||
15–24 | 568,000 (411,000–771,000) | 520,000 (411,000–644,000) | 1,115,000 (914,000–1,350,000) |
25–39 | 1,124,000 (839,000–1,469,000) | 1,471,000 (1,196,000–1,773,000) | 2,648,000 (2,235,000–3,100,000) |
40–59 | 1,462,000 (1,131,000–1,863,000) | 1,495,000 (1,222,000–1,795,000) | 3,005,000 (2,562,000–3,510,000) |
15–59 | 3,278,000 (2,780,000–3,834,000) | 3,536,000 (3,112,000–3,975,000) | 6,861,000 (6,209,000–7,563,000) |
Ordinary differential equation-based modeling assuming equilibrium and static incidence was used to estimate Trichomonas vaginalis incidence. Incidence estimates represent the cumulative number of incident infections in 2018. All counts are rounded to the nearest thousand infections. The uncertainty interval surrounding each point estimate represents the 25th and 75th percentiles of the empirical frequency distribution of the estimate for each infection. The number of incident infections was calculated by multiplying the per-capita incidence estimates by the American Community Survey full population estimates for 2018. Total estimates are not the sum of individual estimates but rather descriptions of multiple distributions that have been combined.